Department of Interventional Radiology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, Harbin 150086, China.
Comput Math Methods Med. 2022 Mar 23;2022:3722703. doi: 10.1155/2022/3722703. eCollection 2022.
To investigate the clinical efficacy of digital subtraction angiography- (DSA-) guided bronchial arterial chemoembolization (BACE) in patients with primary bronchial lung cancer.
A total of 178 patients with primary intermediate and advanced bronchial lung cancer admitted to our hospital from February 2019 to March 2020 were selected as the subjects, and they were divided into control group (84 cases) and observation group (94 cases) according to the different chemotherapy regimens adopted by the patients. The control group was treated with traditional perfusion chemotherapy, and the observation group was treated with DSA-guided BACE interventional therapy, treated for 4 cycles, and followed up until the end of June 2021. The short-term clinical efficacy, hemoptysis remission, and incidence of adverse reactions were compared between the two groups. The mortality and recurrence rates between the two groups from treatment to the end of follow-up were counted, and the quality of life after treatment and 1 year after treatment were compared.
The short-term remission rate (73.40% vs. 58.33%), disease control rate (93.62% vs. 84.52%), hemoptysis remission rate (75.00% vs. 41.51%), the quality of life after chemotherapy cycle (90.86 ± 2.55 vs. 78.04 ± 2.21), and the quality of life after 1 year of follow-up (85.68 ± 2.23 vs. 70.27 ± 1.72) in the observation group were significantly higher than those in the control group, and the difference was statistically significant ( < 0.05). The incidence of adverse reactions (9.57% vs. 20.24%), mortality (10.64% vs. 21.43%), and recurrence rate (11.70% vs. 27.38%) during the follow-up period in the observation group were significantly lower than those in control group, and the differences were statistically significant ( < 0.05).
DSA-guided BACE interventional therapy for patients with primary middle-advanced bronchial lung cancer has significant efficacy, which can not only reduce the mortality and recurrence rate of patients but also improve the quality of life of patients, with fewer adverse reactions and high safety, which is worthy of promotion.
探讨数字减影血管造影（DSA）引导支气管动脉化疗栓塞（BACE）治疗原发性支气管肺癌的临床疗效。
选取 2019 年 2 月至 2020 年 3 月我院收治的 178 例原发性中晚期支气管肺癌患者为研究对象，根据患者采用的化疗方案不同分为对照组（84 例）和观察组（94 例）。对照组采用传统灌注化疗，观察组采用 DSA 引导 BACE 介入治疗，治疗 4 个周期，随访至 2021 年 6 月底。比较两组近期临床疗效、咯血缓解情况及不良反应发生情况。统计两组患者自治疗至随访结束的死亡率和复发率，比较两组患者治疗后及治疗后 1 年的生活质量。
观察组近期缓解率（73.40%比 58.33%）、疾病控制率（93.62%比 84.52%）、咯血缓解率（75.00%比 41.51%）、化疗周期后生活质量（90.86±2.55 比 78.04±2.21）及随访 1 年后生活质量（85.68±2.23 比 70.27±1.72）均显著高于对照组，差异有统计学意义（<0.05）。观察组不良反应发生率（9.57%比 20.24%）、死亡率（10.64%比 21.43%）及随访期间复发率（11.70%比 27.38%）均显著低于对照组，差异有统计学意义（<0.05）。
DSA 引导 BACE 介入治疗原发性中晚期支气管肺癌疗效显著，不仅能降低患者死亡率及复发率，还能提高患者生活质量，不良反应少，安全性高，值得推广。
